Welcome, Guest

Covered Call Income Screener Income Alerts Plus Newsletter MTA Wealthbuilder MT Cash Flow System MT Live Coaching & Library MTA Wealthbuilder SELECT MT Cash Flow System SELECT Video On Demand Lessons Education Live Coaching Calls & Library Market Insight Blog Market Forecast Videos Wealth Path News My Account

Stock News

Enter Stock Symbol

Johnson & Johnson To Acquire Early-Stage Eczema Treatment Developer Proteologix For $850M

Thursday, Johnson & Johnson (NYSE:JNJ) agreed to acquire Proteologix Inc., a privately held biotechnology company focused on bispecific antibodies for immune-mediated diseases, for $850 million in cash, with the potential for an additional milestone payment. Proteologix’s portfolio includes: PX128, a bispecific antibody targeting IL-13 plus TSLP, which is ready to enter phase 1 development for moderate to severe atopic dermatitis (AD) and moderate to severe asthma. PX130, a bispecific antibody t

Thu, 16 May 2024 18:35:58 +0000 — Read more…

Johnson & Johnson to Buy Proteologix For $850 Million in Cash

Thu, 16 May 2024 17:41:01 +0000 — Read more…

Johnson & Johnson (JNJ) Up 5.5% Since Last Earnings Report: Can It Continue?

Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Thu, 16 May 2024 15:30:12 +0000 — Read more…

UPDATE 1-Johnson & Johnson to acquire Proteologix for $850 million

Johnson & Johnson said on Thursday it would acquire Proteologix for $850 million in cash, as it looks to gain access to the privately held company's experimental atopic dermatitis treatments. Proteologix's antibody PX128 is ready to enter early-stage development for moderate to severe atopic dermatitis, commonly referred to as eczema, and moderate to severe asthma. PX130, its other antibody, is in preclinical development for moderate to severe atopic dermatitis.

Thu, 16 May 2024 12:03:41 +0000 — Read more…

Johnson & Johnson to acquire Proteologix for $850 million

Proteologix's antibody PX128 is ready to enter early-stage development for moderate to severe atopic dermatitis, commonly referred to as eczema, and moderate to severe asthma. PX130, its other antibody, is in preclinical development for moderate to severe atopic dermatitis.

Thu, 16 May 2024 11:40:05 +0000 — Read more…

Johnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis Treatment

NEW BRUNSWICK, N.J., May 16, 2024--Johnson & Johnson (NYSE: JNJ) announced today that it has entered into a definitive agreement to acquire Proteologix, Inc., a privately-held biotechnology company focused on bispecific antibodies for immune-mediated diseases, for $850 million in cash, with potential for an additional milestone payment.

Thu, 16 May 2024 11:30:00 +0000 — Read more…

J&J to buy Proteologix and its dual-targeting antibody drugs for $850M

The deal is part of a plan by J&J to build a portfolio of “differentiated” bispecific antibodies, an increasingly popular area of drug development.

Thu, 16 May 2024 11:10:00 +0000 — Read more…

1 No-Brainer Growth Stock to Buy and Hold for 10 Years

This company's potential far outweighs its risks.

Wed, 15 May 2024 14:15:00 +0000 — Read more…

Is Ardagh Metal Packaging SA (NYSE:AMBP) the Best High-Dividend Penny Stock to Buy Now?

Dividend stocks are gaining momentum following major technology companies announcing their first-ever dividends this year. Americans are also starting to prefer dividend equities during the current inflation storm and expectations of a higher-for-longer scenario. In this environment affordable stocks that pay high dividends are in the limelight. We recently covered some of the best high-yield penny dividend stocks […]

Tue, 14 May 2024 17:31:43 +0000 — Read more…

Is B2Gold Corp (NYSE:BTG) the Best High-Dividend Penny Stock to Buy Now?

Tue, 14 May 2024 17:16:19 +0000 — Read more…

Funds Linked to Morgan Stanley, Blue Owl Join Bond Sales Blitz

(Bloomberg) -- Business development companies, which invest in small and mid-sized firms typically too small or risky for banks to lend to, are getting in on a borrowing spree in the booming US investment-grade market.Most Read from BloombergTrump Vows ‘Day One’ Executive Order Targeting Offshore WindBiden Accuses China of ‘Cheating’ on Trade, Imposes New TariffsFlood of China Used Cooking Oil Spurs Call to Hike US LeviesHow One of the World's Oldest Hedge Funds Went BankruptS&P 500 Gets Close t

Tue, 14 May 2024 17:00:11 +0000 — Read more…

Q1 2024 Stereotaxis Inc Earnings Call

Tue, 14 May 2024 13:47:29 +0000 — Read more…

Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.

Tue, 14 May 2024 13:00:15 +0000 — Read more…

Johnson & Johnson's Subsidiary Discontinues Some Megadyne Electrodes For Pediatric Use

Johnson & Johnson’s (NYSE:JNJ) medical device subsidiary is pulling its Megadyne Mega Soft Pediatric Patient Return Electrodes following reports of patient burns. Ethicon’s Megadyne division recalled its Mega Soft and Mega 2000 return electrodes in June 2023. The soft reusable pads are used during electrosurgery. The electrode aims to minimize the risk of electrical burns by ensuring the current flows safely through the patient’s body and back to the electrosurgical unit, preventing any concentr

Mon, 13 May 2024 20:30:43 +0000 — Read more…

Top Midday Stories: Return of 'Roaring Kitty' Lifts GameStop Shares; Intel, Apollo Near Deal on Ireland Plant; BHP Latest Offer Rejected by Anglo American; Squarespace Acquired by Permira; Amazon Autonomous Driving Under Probe

Mon, 13 May 2024 16:27:10 +0000 — Read more…

14 Best Long-Term Dividend Stocks To Buy Now

In this article, we discuss 14 best long-term dividend stocks to buy now. You can skip our detailed analysis of dividend stocks and their previous performance, and go directly to read 5 Best Long-Term Dividend Stocks To Buy Now. For long-term investing, many investors aim for not just growth but a steady stream of income […]

Mon, 13 May 2024 16:10:04 +0000 — Read more…

Johnson & Johnson (JNJ) Could Be a Great Choice

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.

Mon, 13 May 2024 15:45:08 +0000 — Read more…

Takeda shells out $100m to license AC Immune’s Phase II Alzheimer’s therapy

Takeda will pay $100m upfront and up to $2.1bn in milestone-based payments for licensing AC immune’s amyloid beta-targeting immunotherapy.

Mon, 13 May 2024 15:22:11 +0000 — Read more…

Johnson & Johnson to sell remaining stake in Kenvue

Shares of Kenvue (KVUE) are trading slightly higher on Monday after Johnson & Johnson (JNJ) announced it would sell its remaining 9.5% stake in the company. Kenvue will not receive any money from the sale. Yahoo Finance Anchors Seana Smith and Jared Blikre break down the latest developments for these companies. For more expert insight and the latest market action, click here to watch this full episode of Catalysts. This post was written by Nicholas Jacobino

Mon, 13 May 2024 14:55:17 +0000 — Read more…

Sector Update: Consumer Stocks Gain Premarket Monday

Mon, 13 May 2024 13:22:11 +0000 — Read more…